

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

OCT 1 8 2001

Mr. Paul Hooey
President
National Therapy Products, Inc.
2-191 Rowntree Dairy Road
WOODBRIDGE ONTARIO
L4L 8B8 CANADA

Re: K012522

Trade/Device Name: Wavelength Multi-Purpose

Ultrasound Gel

Regulation Number: 21 CFR 892.1570

Regulation Name: Diagnostic Ultrasound transducer

Regulatory Class: II Product Code: 90 ITX Dated: September 21, 2001 Received: September 24, 2001

Dear Mr. Hooey:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at one of the following numbers, based on the regulation number at the top of this letter:

8xx.1xxx	(301) 594-4591
876.2xxx, 3xxx, 4xxx, 5xxx	(301) 594-4616
884.2xxx, 3xxx, 4xxx, 5xxx, 6xxx	(301) 594-4616
892.2xxx, 3xxx, 4xxx, 5xxx	(301) 594-4654
Other	(301) 594-4692

Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html.

Sincerely yours,

Vancy Chrogdon
Nancy C. Brogdon

Director, Division of Reproductive, Abdominal, and Radiological Devices

Office of Device Evaluation

Center for Devices and Radiological Health

Enclosure

Page Oof O

K012322
510(k) Number (if known): KOIZSZZ
Device Name: WAVELENG TH MULTIPURPOSE ULTRASOUND GEL
Indications For Use:
WAVELENATH MULTI-PURPOSE ULTRASOUND
GEL IS INTENDED TO BE USED AS A
COUPLING MEDIUM FOR ULTRASOUND TRANSMISSION.
- 2-1-1-15 T ARISH
APPLY WAVELENGTH TO TREATMENT AREA.
REMOVE AFTER TREATMENT WITH TISSUE OR TOWEL.
CLEAN EQUIPMENT AND RINSE TOWERS
IMMEDIATERY AFTER USE.
NOT FOR USE WITH DEFIBRILLATO
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF W/ NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use (Per 21 CFR 801.109)

(Optional Format 1-2-96)